A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors

ClinicalTrials.gov ID: NCT06983743

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT06983743. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 14, 2026, 3:47 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1 First-in-Human Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of ERAS-0015 Monotherapy and in Combination in Patients Advanced Solid Tumors

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The main purpose of the study is to assess whether the study drug, ERAS-0015, is safe and tolerable when administered to patients with advanced or metastatic solid tumors with certain RAS mutations. ERAS-0015 will be given alone or in combination with other treatments.

Study identification

NCT ID: NCT06983743
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: Erasca, Inc.; Industry
Enrollment: 600 participants

Conditions and interventions

Conditions

Metastatic Solid Tumors

Interventions

ERAS-0015 Drug
ERAS-0015 in combination Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 99 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jun 5, 2025 (Actual)
Primary completion: May 1, 2028 (Estimated)
Completion: Dec 1, 2028 (Estimated)
Last update posted: Nov 6, 2026

2025 – 2028

United States locations

U.S. sites: 10
U.S. states: 8
U.S. cities: 10

Facility	City	State	ZIP	Site status
Providence Medical Group	Santa Rosa	California	95403	Recruiting
University of Colorado	Aurora	Colorado	80045	Recruiting
Florida Cancer Specalists	Sarasota	Florida	34232	Recruiting
Moffitt Cancer Center	Tampa	Florida	33612	Recruiting
Emory University	Atlanta	Georgia	30307	Recruiting
Massachusetts General Hospital (MG)	Boston	Massachusetts	02114	Recruiting
Memorial Sloan Kettering Cancer Center	New York	New York	10065	Recruiting
The University of Texas MD Anderson Cancer Center	Houston	Texas	77030	Recruiting
University of Texas at Tyler	Tyler	Texas	75701	Recruiting
NEXT Virginia	Fairfax	Virginia	22031	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06983743, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Nov 6, 2026 · Synced Nov 14, 2026